Pneumonia
Conditions
Keywords
Intensive Care Unit (ICU), Intensive Respiratory Care Unit (USIP), Intermediate Care Unit (USC), Chlamydia pneumoniae, Mycoplasma pneumoniae, Infection
Brief summary
The ECRAN-PLASMA study aims to analyze the characteristics of patients with Mycoplasma pneumoniae or Chlamydia pneumoniae pneumonia hospitalized in intensive care units (ICU), continuous monitoring units (USC), or intensive pulmonary care units (USIP). It evaluates their management, prognosis, and macrolide resistance rates.
Detailed description
The ECRAN-PLASMA study focuses on Mycoplasma pneumoniae and Chlamydia pneumoniae infections in intensive care units (ICU), continuous monitoring units (USC), and intensive pulmonary care units (USIP). It aims to better understand the epidemiology, management, and prognosis of these infections, particularly in light of the resurgence of cases following the COVID-19 pandemic and the increasing resistance to macrolides. Mycoplasmas are bacteria lacking a cell wall, making them resistant to beta-lactam antibiotics. M. pneumoniae adheres to the respiratory epithelium and produces a toxin (CARD-TX) that plays a role in disease pathogenesis. Transmission occurs through aerosols and droplets, with its prevalence likely underestimated due to often mild symptoms. However, in elderly or vulnerable patients, the infection can progress to severe forms requiring intensive care hospitalization, with a significant mortality rate. The study includes all patients hospitalized in USC, USIP, or ICU who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae during the inclusion period. Its main objectives are to describe patient characteristics, assess factors associated with disease severity and prognosis, and analyze macrolide resistance. Expected outcomes include estimating the incidence of Mycoplasma pneumoniae and Chlamydia pneumoniae pneumonia in intensive care settings, gaining a better understanding of at-risk patient profiles, and optimizing patient management. The study also aims to improve prevention strategies and guide future clinical research on these infections.
Interventions
OTHERInfectious disease epidemiology
evaluation of patient management, prognosis, and macrolide resistance rates in severe Mycoplasma pneumoniae and Chlamydia pneumoniae infections.
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Screening of all patients hospitalized in Intermediate Care Units (USC), Intensive Respiratory Care Units (USIP), and Intensive Care Units (ICU) * Inclusion of patients who test positive for Mycoplasma pneumoniae or Chlamydia pneumoniae
Exclusion criteria
* Patients under 18 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Severe Mycoplasma pneumoniae and Chlamydia pneumoniae Infections | From hospital admission to hospital discharge (up to 60 days) | Number of patients hospitalized in ICU, USC, or USIP with a confirmed diagnosis of Mycoplasma pneumoniae or Chlamydia pneumoniae. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| In-hospital Mortality Rate | From hospital admission to hospital discharge (up to 60 days) | Proportion of patients who died during the index hospitalization among patients with confirmed infection, assessed from medical records. |
| Length of Stay in ICU and Hospital | From hospital admission to hospital discharge (up to 60 days) | Number of days spent in the ICU and total hospitalization duration. |
| Macrolide Resistance Rate | At time of microbiological diagnosis (baseline) | Percentage of patients infected with a macrolide-resistant strain. |
| Need for invasive mechanical ventilation | From hospital admission to hospital discharge (up to 60 days) | Proportion of patients requiring invasive mechanical ventilation during hospitalization, assessed from medical records. |
| Use of respiratory and supportive therapies | From hospital admission to hospital discharge (up to 60 days) | Proportion of patients receiving each therapeutic modality (oxygen therapy, non-invasive ventilation, invasive mechanical ventilation, ECMO) during hospitalization, assessed from medical records. |
| Time from Symptom Onset to ICU Admission | At patient admission. | Time elapsed between the onset of symptoms and hospitalization in USC, USIP, or ICU. |
| In-hospital mortality compared with other bacterial pneumonias | From hospital admission to hospital discharge (up to 60 days) | Difference in in-hospital mortality rates between patients with Mycoplasma or Chlamydia pneumoniae infection and patients with other bacterial pneumonias, assessed from medical records. |
| Vital status at hospital discharge | During hospitalization (up to 60 days) | Proportion of patients alive at hospital discharge, assessed from medical records. |
| Respiratory support at hospital discharge | During hospitalization (up to 60 days) | Proportion of patients requiring respiratory support (oxygen therapy or mechanical ventilation) at hospital discharge, assessed from medical records. |
| Occurrence of acute respiratory distress syndrome (ARDS) | From hospital admission to hospital discharge (up to 60 days) | Proportion of patients who developed acute respiratory distress syndrome during hospitalization, assessed from medical records. |
Countries
France
Outcome results
None listed